Table 2 In vitro antifungal activity of azoles and essential oils against Cryptococcus neoformans azole-susceptible and not-susceptible clinical isolates
Yeast strains | Antifungal drugs (μg/ml) | Essential oils and main components (mg/ml) | |||||||
|---|---|---|---|---|---|---|---|---|---|
MIC/MFC | MIC/MFC | ||||||||
FLC | VRC | ITC | Origanum vulgare | Pinus sylvestris | Thymus vulgaris | (+)-α-pinene | Carvacrol | Thymol | |
ADS 16 | 0.25/4 | 0.015/0.06 | 0.5/0.5 | 0.3/0.3 | 0.27/0.54 | 0.56/1.12 | 1.07/1.07 | 0.6/1.2 | 0.02/0.04 |
ADS 37 | 0.25/4 | 0.06/0.25 | 0.5/0.5 | 0.3/0.6 | 0.14/0.14 | 0.56/0.56 | 0.54/0.54 | 0.6/1.2 | 0.04/0.04 |
ADS 48 | 0.5/8 | 0.015/0.06 | 0.25/0.5 | 0.3/0.3 | 0.14/0.14 | 0.56/0.56 | 0.54/0.54 | 0.6/0.6 | 0.04/0.08 |
ADS 57 | 4/32 | 0.125/0.5 | 0.5/0.5 | 0.3/0.3 | 0.07/0.14 | 1.12/1.12 | 0.54/0.54 | 0.6/1.2 | 0.04/0.04 |
ADS 108 | 0.25/4 | 0.015/0.06 | 0.25/0.5 | 0.6/0.6 | 0.07/0.07 | 0.56/1.12 | 0.54/0.54 | 0.6/0.6 | 0.04/0.04 |
ADS 109 | 4/32 | 0.015/0.06 | 0.25/0.5 | 0.6/0.6 | 0.14/0.27 | 1.12/1.12 | 0.54/1.07 | 0.6/1.2 | 0.04/0.08 |
ADS 006 | > 128/> 128 | > 32/> 32 | 2/> 2 | 0.3/1.2 | 0.54/1.1 | 1.12/2.24 | 1.07/1.07 | 0.6/0.6 | 0.08/0.16 |